• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Evaluation of the effect of sodium zirconium cyclosilicate on arrhythmia-related cardiovascular outcomes in patients receiving chronic haemodialysis with hyperkalaemia: protocol for the multicentre, randomised, controlled DIALIZE-Outcomes study
Introduction Patients with kidney failure receiving chronic haemodialysis have elevated risk of arrhythmias potentially increasing the likelihood of sudden cardiac death, stroke and hospitalisation. The DIALIZE study (NCT03303521) demonstrated that sodium zirconium cyclosilicate (SZC) was an efficacious and well-tolerated treatment for predialysis hyperkalaemia in patients undergoing haemodialysis. The DIALIZE-Outcomes study evaluates the effect of SZC on sudden cardiac death and arrhythmia-related cardiovascular outcomes in patients receiving chronic haemodialysis with recurrent hyperkalaemia. Methods and analysis Intern...
Source: BMJ Open - May 25, 2023 Category: General Medicine Authors: Fishbane, S., Jadoul, M., Dember, L., Kovesdy, C., Al-Shurbaji, A., Lisovskaja, V., Sekar, P., Katona, B., Guzman, N., Herzog, C. Tags: Open access, Renal medicine Source Type: research

Effect of sodium bicarbonate on cardiovascular outcome and mortality in patients with advanced chronic kidney disease
Conclusion: The cohort study found that in real world practice, among patients with advanced CKD stage V, use of sodium bicarbonate was associated with similar risk of dialysis compared with non-users, Nonetheless, use of sodium bicarbonate was associated with significantly lower rate of MACE and mortality. The study results reinforced the benefits of sodium bicarbonate therapy in the expanding CKD population. Further prospective studies are needed to confirm these findings.
Source: Frontiers in Pharmacology - May 11, 2023 Category: Drugs & Pharmacology Source Type: research

SGLT2 Inhibitors: The Next Blockbuster Multifaceted Drug?
Medicina (Kaunas). 2023 Feb 16;59(2):388. doi: 10.3390/medicina59020388.ABSTRACTSodium glucose cotransporter 2 inhibitor (SGLT2i) is a class of drugs that were originally intended for decreasing blood glucose in diabetes. However, recent trials have shown that there are other beneficial effects. Major clinical trials involving SGLT2i medications from 2015 to 2022 were reviewed using PUBMED search. Recent major SGLT2i landmark trials have demonstrated benefits for cardiovascular disease (reduce major adverse cardiovascular events (heart attack, stroke, cardiovascular death), hospitalization for heart failure, all-cause deat...
Source: Medicina (Kaunas) - February 25, 2023 Category: Universities & Medical Training Authors: Jonathan C H Chan Michael C Y Chan Source Type: research

Pages: 1  2  3